Glycemia reduction in type 2 diabetes-Hypoglycemia outcomes: A randomized clinical trial.

Seaquist ER, Phillips LS, Ghosh A, Baker C, Bergenstal RM, Crandall JP, Goland RS, Gramzinski MR, Hox SH, Hsia DS, Johnson ML, Lachin JM and 4 more

Show all authors

Raskin P, Valencia WM, Waltje AH, Younes N

PloS one15 Nov 2024Cited by 4 (Europe PMC)

PMID39546502PMCIDPMC11567630DOI10.1371/journal.pone.0309907PepBankPUB-39546502

Source link PubMedAsk about this study

Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

01HumanRandomized controlled trialSafety outcome
In metformin-treated adults with type 2 diabetes, severe hypoglycemia occurred in 6 participants (0.5%) with liraglutide, across four arms (p<0.05).
In plain wordsIn adults with type 2 diabetes taking metformin, severe low blood sugar occurred in 0.5% of those given liraglutide, compared across four drug groups.
Peptide
Liraglutide
Outcome
Not applicableSevere hypoglycemia events
Study
n = 4,830
Comparator
Glargine U100, glimepiride, sitagliptin (added to metformin)
Outcome group
Adverse events · Endocrine and hormones
Studied dose
Dose not stated · 5.0 ± 1.3 years (mean ± SD)As given in this study (human).
Measurements
Severe hypoglycemia
6 participants
liraglutide
Severe hypoglycemia
0.5%
liraglutide
Source sentences
Summary
While participants were taking their assigned medications, severe hypoglycemia occurred in 10 (0.8%), 16 (1.3%), 6 (0.5%), and 4 (0.3%), (p<0.05) and hypoglycemic symptoms in 659 (54.2%), 833 (68.3%), 375 (32.4%), and 361 (29.1%) of participants following randomization to glargine, glimepiride, lira…
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized, controlled trial of 5,047 participants with T2DM of <10 years' duration, hemoglobin A1c (HbA1c) 6.8-8.5% (50.8-69.4 mmol/mol).
Summary · context
Randomization to addition of glargine U100, glimepiride, liraglutide, or sitagliptin over 5.0 ± 1.3 (mean ± SD) years.
Report a problemFND-3954650201
02HumanRandomized controlled trialSafety outcome
In metformin-treated adults with type 2 diabetes, hypoglycemic symptoms occurred in 375 participants (32.4%) with liraglutide, across four arms (p<0.001).
In plain wordsIn adults with type 2 diabetes taking metformin, low blood sugar symptoms occurred in 32.4% of those given liraglutide, compared across four drug groups.
Peptide
Liraglutide
Outcome
Not applicableHypoglycemic symptoms
Study
n = 4,830
Comparator
Glargine U100, glimepiride, sitagliptin (added to metformin)
Outcome group
Adverse events · Endocrine and hormones
Studied dose
Dose not stated · 5.0 ± 1.3 years (mean ± SD)As given in this study (human).
Measurements
Hypoglycemic symptoms
375 participants
liraglutide
Hypoglycemic symptoms
32.4%
liraglutide
Source sentences
Summary
While participants were taking their assigned medications, severe hypoglycemia occurred in 10 (0.8%), 16 (1.3%), 6 (0.5%), and 4 (0.3%), (p<0.05) and hypoglycemic symptoms in 659 (54.2%), 833 (68.3%), 375 (32.4%), and 361 (29.1%) of participants following randomization to glargine, glimepiride, lira…
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized, controlled trial of 5,047 participants with T2DM of <10 years' duration, hemoglobin A1c (HbA1c) 6.8-8.5% (50.8-69.4 mmol/mol).
Summary · context
Randomization to addition of glargine U100, glimepiride, liraglutide, or sitagliptin over 5.0 ± 1.3 (mean ± SD) years.
Report a problemFND-3954650202

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01794143

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

GRADE Study Groupn = 7,850May 2013 to 30 Apr 2021

Type 2 Diabetes · Comparative Effectiveness of Glycemia-lowering Medications

Trial page ClinicalTrials.govUpdated 10 Feb 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.